InMed Pharmaceuticals Inc (INM)vsNovartis AG ADR (NVS)

INM

InMed Pharmaceuticals Inc

NASDAQ

$0.70

0.00%

HEALTHCARE · Cap: $2.43M

NVS

Novartis AG ADR

NYSE

$147.85

+3.44%

HEALTHCARE · Cap: $282.11B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 1255348% more annual revenue ($56.58B vs $4.51M). NVS leads profitability with a 23.9% profit margin vs -170.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).

INM

Avoid

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0

NVS

Buy

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INM.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INM1 strengths · Avg: 10.0/10

Price/BookValuation

0.2x10/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

INM4 concerns · Avg: 2.8/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$2.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability

-97.2%2/10

ROE of -97.2% — below average capital efficiency

Revenue GrowthGrowth

-26.2%2/10

Revenue declined 26.2%

NVS4 concerns · Avg: 3.0/10

PEG RatioValuation

2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth

-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : INM

The strongest argument for INM centers on Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : INM

The primary concerns for INM are EPS Growth, Market Cap, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

INM profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.52 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 31/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InMed Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

INM vs TAK INM vs ZTS INM vs HLN INM vs TEVA INM vs UTHR NVS vs TAK NVS vs ZTS NVS vs HLN NVS vs TEVA NVS vs UTHR

Want to dig deeper into these stocks?

Full INM Analysis →Full NVS Analysis →